EODData

MEMBERSHIP REGISTER LOG IN

FRA, ICY: Incyte Corporation

09 Feb 2026
LAST:

90.56

CHANGE:
 4.04		OPEN:
90.80		HIGH:
90.80		ASK:
0.00		VOLUME:
30
CHG(%):
4.67		PREV:
86.52		LOW:
90.56		BID:
0.00		 

CHART

RECENT END OF DAY PRICES

DateOpenHighLowCloseVolume
09 Feb 2690.8090.8090.5690.5630
06 Feb 2686.5286.5286.5286.52120
05 Feb 2686.7486.7486.7486.74120
04 Feb 2684.9085.8684.9085.86120
03 Feb 2686.8086.8086.8086.8010
02 Feb 2682.7684.9682.7684.960
30 Jan 2683.7484.5683.7484.5650
29 Jan 2684.1684.9684.1684.9692
28 Jan 2685.8485.9283.3883.3847
27 Jan 2686.3087.6485.7487.64146

PROFILE

Name:Incyte Corporation
About:Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI (ruxolitinib) for the treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for treating relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a selective fibroblast growth factor receptor kinase inhibitor for the treatment of unresectable biliary tract cancer, metastatic cholangiocarcinoma, and myeloid/lymphoid neoplasms; ICLUSIG (ponatinib), a kinase inhibitor to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma; and NIKTIMVO (axatilimab-csfr) for treating chronic graft-versus-host disease, as well as OPZELURA (ruxolitinib) cream for treating atopic dermatitis. Its clinical stage products include INCB123667 (CDK2) for ovarian cancer; INCB161734 (KRASG12D) for cancers; INCA33890 (TGFßR2xPD-1) for solid tumors; Ruxolitinib cream for mild to moderate hidradenitis suppurativa (HS); Povorcitinib for HS, nonsegmental vitiligo, prurigo nodularis, and asthma and chronic spontaneous urticaria; INCB000262 (MRGPRX2) and INCB000547 (MRGPRX4) for systemic immune and neuro-immune disorders; INCA034460 (anti-CD122) for vitiligo; and Zilurgisertib (ALK2) for fibrodysplasia ossificans progressive. It has collaboration with Genesis Therapeutics, Inc. The company sells its products to specialty and retail pharmacies, hospital pharmacies, and specialty distributors and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation was incorporated in 1991 and is headquartered in Wilmington, Delaware.
Sector:Healthcare
Industry:Biotechnology
Address:1801 Augustine Cut-Off, Wilmington, DE, United States, 19803
Website:https://www.incyte.com
ISIN:US45337C1027
LEI:549300Z4WN6JVZ3T4680

API SERVICE  NEW

Have you tried our new API Service yet?

For more information, visit our API page.

You can get your ApiKey over HERE.

If you're ready to get going, then jump over to:
https://api.eoddata.com

SYMBOL HISTORY

   Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

  Download

FUNDAMENTALS

Trailing P/E:17.10 
Forward P/E:19.42 
PEG Ratio:19.42 
Price to Sales:3.53 
Price to Book:4.26 
Profit Margin:0.25 
Operating Margin:0.32 
Return on Assets:0.14 
Return on Equity:0.30 
Revenue:4.089B 
EBITDA:1.245B 
Shares:195.28M 
Market Cap:17.684B 

TECHNICAL INDICATORS

MA5:87.303.7%
MA10:86.205.1%
MA20:87.693.3%
MA50:87.303.7%
MA100:82.699.5%
MA200:71.6726.4%
STO9:96.77 
STO14:96.77 
RSI14:52.01
MTM14:2.00
ROC14:0.02 
ATR:1.87 
Week High:90.800.3%
Week Low:82.769.4%
Month High:92.502.1%
Month Low:82.7626.4%
Year High:95.565.5%
Year Low:49.0284.7%
Volatility:34.58